CorA veterinary
- Summary
- Corallopyronin A is a new antibiotic in filarial and dirofilarial infections with a new mode of action resulting in fewer adverse reaction and unlikelyness of resistances development.
- Technology Benefits
- Effective control of dirofilarial infections
High efficacy against the bacteria Wolbachia – potential for killing larvae as well as adult worms
Oral administration is probable
Slow worm death prevents potential pulmonary thromboembolism
Is likely to be well tolerated and could be used in all dog races, e. g. Collies
Will probably be suitable for the treatment of pregnant dogs
- Technology Application
- A promising approach for Heartworm disease is to target the Wolbachia with CorA. Prophylactic and therapeutic treatment.
- Detailed Technology Description
- Corallopyronin A (CorA) has efficacy against the intracellular Wolbachia of filarial nematodes. Experiments in mice and jirds show that all worms were depleted of their Wolbachia by more than 98%, resulting in blocked larval development and phenotypically altered worms. The results indicate the potential of CorA to effectively kill filarial nematodes in the larval stages as well as adult worms. Thus, this antibiotic is a good option for prophylactic as well as therapeutic treatment.
- Type of Cooperation
- Licensing
- Application Date
- 04.05.2012
- Application No.
- EP20120721456 20120504
- Classes
- - international:
A61K31/366; A61P31/04; A61P33/00
- cooperative:
A61K31/366; C07D309/38; Y02A50/421; Y02A50/422
- Others
- Patent application
- ID No.
- 2838
- Country/Region
- Germany
For more information, please click Here
